TRVI NASDAQ
Trevi Therapeutics, Inc.
1W: +4.0%
1M: -7.3%
3M: -26.2%
YTD: +12.3%
1Y: +27.0%
3Y: +645.8%
5Y: +1021.9%
$13.35
+0.84 (+6.71%)
Weekly Expected Move ±5.9%
$11
$12
$13
$13
$14
Credit Risk of going bust: lower than 92% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Trevi Therapeutics, Inc. would be worth roughly what it owes.
Total debt $605K against a stock market value of $1.90B.
Distance to default 14.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $302K (short-term plus half of long-term), stock volatility 57.6%; Altman Z'' 39.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Trevi Therapeutics, Inc. would be worth roughly what it owes.
Total debt $605K against a stock market value of $1.90B.
Distance to default 14.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $302K (short-term plus half of long-term), stock volatility 57.6%; Altman Z'' 39.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range9.82-20.22
Volume2,094,310
Avg Volume2,272,310
Beta0.98
Dividend—
Analyst Ratings
Company Info
CEOJennifer L. Good
Employees34
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-07
Websitetrevitherapeutics.com
195 Church Street
New Haven, CT 06510
US
New Haven, CT 06510
US
203 304 2499
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Latest News
Trevi Therapeutics (NASDAQ:TRVI) Stock Sees Heavy Call Option Buying
Bank of America Corp DE Invests $28.59 Million in Trevi Therapeutics, Inc. $TRVI
Bank of New York Mellon Corp Invests $5.72 Million in Trevi Therapeutics, Inc. $TRVI
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A.
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Heffernan Michael Th | M-Exempt | 18,421 | $3.04 | 2026-09-15 |
| Heffernan Michael Th | S-Sale | 20,952 | $15.09 | 2026-09-15 |
| Heffernan Michael Th | S-Sale | 100 | $15.88 | 2026-09-15 |
| Heffernan Michael Th | M-Exempt | 21,052 | $3.33 | 2026-09-15 |
| Heffernan Michael Th | M-Exempt | 18,421 | $3.04 | 2026-09-15 |